Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Majed Altareb"'
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S48- (2021)
Objective: To study the outcomes of allo-HCT in patients with hematological malignancy who received BU3 (9.6 mg/kg) based conditioning from matched related or unrelated donors. Methodology: A retrospective analysis of KFSHRC- BMT Database, we identif
Externí odkaz:
https://doaj.org/article/990786919fe843c4b5cddd2870568c6b
Autor:
Majed Altareb, Moheeb Al-Awwami, Feras Alfraih, Saud Alhayli, Syed Osman Ahmed, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Hana Alkhabbaz, Abdulwahab A. Albabtain, Mansour Alfayez, Amr Hanbali, Alfadel Alshaibani, Ahmad S. Alotaibi, Walid Rasheed, Amal Algharably, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud Aljurf, Riad El Fakih
Publikováno v:
Bone Marrow Transplantation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::176c4b3401f49b2035d98a20b488ac3c
https://doi.org/10.1038/s41409-023-01950-4
https://doi.org/10.1038/s41409-023-01950-4
Autor:
Riad El Fakih, Majed Altareb, Moheeb Al-Awwami, Feras Alfraih, Saud Alhayli, Ahmed Syed, Marwan Shaheen, Naeem Chaudhri, F Al Sharif, Hana Alkhabbaz, Abdulwahab Albabtain, Mansour Alfayez, Amr Hanbali, Alfadel Alshaibani, Ahmad Alotaibi, Walid Rasheed, Amal Algharably, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud D Aljurf
Background: primary graft failure is a devastating complication after allogeneic transplant. Donor specific antibodies has been reported as a major risk factor contributing to graft failure. We retrospectively analyzed our haploidentical transplant r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b052f618f1f0ae8b6f1a75b98079ae74
https://doi.org/10.21203/rs.3.rs-2515886/v1
https://doi.org/10.21203/rs.3.rs-2515886/v1
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S431-S432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da09b5874c4067fec6e95bbf8b6c122
https://doi.org/10.1016/s2152-2650(22)01641-x
https://doi.org/10.1016/s2152-2650(22)01641-x
Publikováno v:
Journal of Applied Hematology. 14:52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ce47f255b81496900f9bf00013021aa
https://doi.org/10.4103/joah.joah_10_21
https://doi.org/10.4103/joah.joah_10_21
Autor:
Momen Nassani, Walid Rasheed, Majed Altareb, Ali Alsharif, Feras Alfraih, Amr Hanbali, Saud Alhayli, Syed Osman Ahmed, Abdulwahab A. Albabtain, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Alfadel Alshaibani, Ahmad S. Alotaibi, Tusneem Elhassan, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud Aljurf, Riad El Fakih
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S436
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c3e2e1554aadebe7358671626f53d7f
https://doi.org/10.1016/s2152-2650(22)01651-2
https://doi.org/10.1016/s2152-2650(22)01651-2
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dea13298ccb571c39bfa5c8183006c76
https://doi.org/10.1016/s2152-2650(22)01149-1
https://doi.org/10.1016/s2152-2650(22)01149-1
Autor:
Momen Nassani, Walid Rasheed, Majed Altareb, Ali Alsharif, Feras Alfraih, Amr Hanbali, Saud Alhayli, Syed Osman Ahmed, Abdulwahab A. Albabtain, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Alfadel Alshaibani, Ahmad S. Alotaibi, Tusneem Elhassan, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud Aljurf, Riad El Fakih
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bace901e663f5e79268da276fb1b112
https://doi.org/10.1016/s2152-2650(22)01156-9
https://doi.org/10.1016/s2152-2650(22)01156-9
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
We report a rare case of a 21 year old male patient known to have chronic myeloid leukemia (CML) with progression to T-cell lymphoblastic lymphoma (T-cell LBL) as extra-medullary blast crisis of CML. Patient was treated by pediatric chemotherapy regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b42042e93fa8394961535c8b96ac68
https://doi.org/10.1016/s2152-2650(21)01764-x
https://doi.org/10.1016/s2152-2650(21)01764-x
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S452-S453
Introduction Busulfan is often used in a myeloablative conditioning regimen at an IV dose of 12.8 mg/kg (BU4). A reduced intensity regimen using 6.4 mg/kg (BU2) is commonly used in older patients or those with comorbid diseases. Data on use of BU3 (9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::041284948d315a5140a1aa663ea82dd6
https://doi.org/10.1016/s2152-2650(21)02004-8
https://doi.org/10.1016/s2152-2650(21)02004-8